戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nce, and up to a 100-fold increase in plasma thromboxane B2.
2 GE2, PGF2 alpha, PGD2, 8-iso-PGF2 alpha, and thromboxane B2.
3 ionship between PCSK9 and urinary 11-dehydro-thromboxane B2 (11-dh-TxB2), a marker of platelet activa
4 creases in concentrations of prostaglandins, thromboxane B2, 15-HETE and 11-HETE in cerebellar sample
5 helial cell adhesion molecule-1, P-selectin, thromboxane B2, 6-ketoprostaglandin F1a, vascular cell a
6 nduced increases in plasma concentrations of thromboxane B2 (60 mins) and significantly (p < .05) pot
7                                 In contrast, thromboxane B2, a cyclooxygenase product that does not p
8                    We analyzed whether serum thromboxane B2, a stable metabolite of thromboxane A2, m
9 ls of leukotriene B4, leukotriene C4/D4, and thromboxane B2 above those of saline-treated rats with f
10                                    Levels of thromboxane B2 and 12-hydroxyeicosatetraenoic acid produ
11 ines (TNF-alpha, IL-6, CXCL8), IL-12, CCL11, thromboxane B2 and immunoglobulin E at 24 h after local
12 and isofuranes, markers of oxidative stress, thromboxane B2 and immunoglobulin E were measured in bro
13                      In contrast, both serum thromboxane B2 and urinary excretion of its 11-dehydro m
14 mporal correlation with elevations of plasma thromboxane B2 and were inhibited by an anti-C5a monoclo
15 yl leukotrienes, leukotriene B4 , 11-dehydro-thromboxane B2 , and prostaglandins E2 , D2 , and F2alph
16 ed in three BoPH: leukotriene E4, 11-dehydro-thromboxane B2, and 2,3-dinor thromboxane B2 on Day 7 in
17 onic acid-derived mediators, leukotriene B4, thromboxane B2, and prostaglandin E2 from stimulated alv
18 flammatory leukotriene B4 and procoagulating thromboxane B2, as well as lower specialized proresolvin
19 nd activation were assessed by aggregometry, thromboxane B2 assay, or FACS.
20 al side effects and did not inhibit platelet thromboxane B2 at plasma drug levels similar to those ob
21                                    Ratios of thromboxane B2,/B3, leukotriene B4/B5, and prostaglandin
22 tory PGE(2) , as well as PGE(1) , PGD(1) and thromboxane B2 but increased prostacyclin, and eicosapen
23 increased (p < .05) plasma concentrations of thromboxane B2 by seven- to eight-fold at 30 to 120 mins
24 -PLC and the formation of prostaglandins and thromboxane B2 by the action of COX as compared to low d
25  factor-alpha, as well as leukotriene C4 and thromboxane B2, by human monocyte-derived macrophages.
26 lush grade=3 exhibited lower values of serum thromboxane B2 compared with those with myocardial blush
27                                              Thromboxane B2 concentration increased significantly in
28                                              Thromboxane B2 concentrations increased transiently in t
29  dramatic increases in plasma and lung lymph thromboxane B2 concentrations.
30 looxygenase metabolites prostaglandin E2 and thromboxane B2 differed at baseline.
31      Furthermore, the recovery of 11-dehydro-thromboxane B2 excretion in two patients after the admin
32 assay for the clopidogrel response and serum thromboxane B2 for the aspirin response) and aggregation
33 tivities, and eicosanoid (prostaglandins and thromboxane B2) formation from arachidonic acid via cycl
34  the rate of formation of prostaglandins and thromboxane B2 from [14C]arachidonic acid.
35      SC-560 inhibited COX-1-derived platelet thromboxane B2, gastric PGE2, and dermal PGE2 production
36 rinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans.
37                                              Thromboxane B2 levels in plasma also decreased monotonic
38 serum hemolytic activity and increase plasma thromboxane B2 levels in rats.
39 ffect of SC-58635 on platelet aggregation or thromboxane B2 levels, whereas aspirin caused significan
40  in 2 of 3 platelet aggregation measures and thromboxane B2 levels.
41           VerifyNow Aspirin assays and serum thromboxane B2 measurements were performed.
42 E4, 11-dehydro-thromboxane B2, and 2,3-dinor thromboxane B2 on Day 7 in the Vuse Solo and Abstinence
43 pe of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a bio
44 nary biomarker evidence of activation of the thromboxane B2 pathway.
45     Although LTB4 levels were reduced, renal thromboxane B2 production and cytokine expression were n
46 ted arachidonic acid-induced aggregation and thromboxane B2 production by > or = 99% (P<0.0001).
47 staglandin E2, 6-ketoprostaglandin F1 alpha, thromboxane B2) production were measured at baseline, po
48 , M1 and M2 phenotypes were distinguished by thromboxane B2, prostaglandin (PG) E2, and PGD2 producti
49 lyzed for leukotriene B4, leukotriene C4/D4, thromboxane B2, prostaglandin E2, 6 keto-prostaglandin F
50 ons of leukotriene B4, prostaglandin E2, and thromboxane B2 released from A23187-stimulated alveolar
51                              Serum levels of thromboxane B2, reperfusion indexes (corrected Thromboly
52 F=3.64; P=0.01334) and correlated with serum thromboxane B2 (rho=0.31; P=0.0413) in control but not i
53 erent eicosanoids, both prostaglandin E2 and thromboxane B2 significantly enhanced serum-induced germ
54                                        Serum thromboxane B2 significantly increased after 120 minutes
55                                        Serum thromboxane B2 (sTXB2), a validated biomarker of platele
56                      Levels of PGF2alpha and thromboxane B2 (TXB2 ) were quantified by ELISA, and PGF
57 plasma creatinine (CR); urea nitrogen (BUN); thromboxane B2 (TXB2) and 6-keto prostaglandin F(1alpha)
58 etter understand aspirin "resistance," serum thromboxane B2 (TXB2) and flow cytometric measures of ar
59 interleukin 6 (IL-6) and the lipid mediators thromboxane B2 (TxB2) and prostacyclin in hypothermic se
60 y the rate and extent of inhibition of serum thromboxane B2 (TXB2) generation.
61   Limits of detection ranged from 0.5 pg for thromboxane B2 (TxB2) to 10 pg for 6-keto prostaglandin
62 ve velocity (PWV), malondialdehyde (MDA) and thromboxane B2 (TxB2) were assessed in the acute and chr
63 e P-selectin, soluble CD40 ligand, and serum thromboxane B2 (TxB2) were measured.
64  lipopolysaccharide: prostaglandin E2 (PGE2)>thromboxane B2 (TxB2)>6-keto prostaglandin F1alpha (PGF1
65 reased formation of prostaglandin E2 (PGE2), thromboxane B2 (TxB2), and 8-epi-PGF2 alpha, but not of
66                                       Plasma thromboxane B2 (TxB2), prostaglandin 6-keto-F1alpha (PGI
67 le metabolite of prostaglandin I2 (PGI2) and thromboxane B2 (TXB2), the stable metabolite of TXA2, vi
68                       We now explore whether thromboxane B2 (TxB2)-like compounds, termed B2-isothrom
69 4 (PF4), beta-thromboglobulin (beta-TG), and thromboxane B2 (TXB2).
70 se was blunted significantly (peak pulmonary thromboxane B2 [TXB2] concentration = 668 pg/ml, p < 0.0
71 din E2, 11-hydroxyeicosatetraenoic acid, and thromboxane B2 were identified as differentiating metabo
72 -VI,2,3-dinor-6-keto-PGF1alpha and 2,3-dinor-thromboxane B2 were increased in GhOEs, reflecting incre
73                   While prostaglandin E2 and thromboxane B2 were previously associated with lung infl
74 e counted, and serum levels of piroxicam and thromboxane B2 were quantitated.
75 ene C4/D4, 6-keto-prostaglandin F1alpha, and thromboxane B2 with corn oil were significantly increase